11.11.2008 – 07:35

Intercell AG

euro adhoc: Intercell AG
Financial Figures/Balance Sheet
Approvals for Japanese Encephalitis vaccine in U.S., Europe and Australia on track for 2008 - All development programs progressing according to plan - Profitability expected for full year ...

  Disclosure announcement transmitted by euro adhoc. The issuer is responsible
  for the content of this announcement.

9-month report

11.11.2008

Intercell successfully advanced parallel regulatory processes in all 
key markets for travelers and military personnel - Vaccine against 
Japanese Encephalitis expected to obtain market approval in the U.S.,
Europe and Australia in 2008 - U.S. Defense Logistics Agency Request 
for Proposal (RFP) for purchase of Japanese Encephalitis (JE) vaccine
for U.S. military in negotiation

» United States: On October 20, the U.S. Food and Drug Administration
(FDA) gave positive feedback on Intercell's application to market its
vaccine against Japanese Encephalitis; Intercell and the agency are 
working   towards the earliest possible approval - ACIP meeting 
discussion on future   recommendation of JE vaccine held on October 
22/23 with formal decision   expected at the February 2009 meeting

» Europe: Approval process advancing according to plan - Intercell 
expects a   positive opinion from EMEA in December 2008

» Australia: Positive approval decision is expected in December 2008

» Intercell has geared up manufacturing efforts to ensure timely 
product   delivery to the U.S. military by the end of 2008 and for 
commercial product   launch in the United States, Europe and 
Australia in early 2009

Integration of recent acquisition of IOMAI successfully implemented -
Focus now on aggressively progressing Travelers' Diarrhea patch 
vaccine and leveraging patch-based products and technologies

» Strategic focus on late-stage development and industrialization of 
the   Travelers' Diarrhea patch vaccine and Pandemic Influenza patch 
vaccine. In   addition, investigation of the use of the patch 
technology in new vaccine   applications has been effectively 
initiated

» Start of pivotal Phase III for Travelers' Diarrhea patch vaccine 
expected   in H1 2009

» Start of Phase II Pandemic flu vaccine expected in H1 2009

Nosocomial infections - S. aureus vaccine and Pseudomonas vaccine 
progressing in clinical programs - All other development programs and
partnerships on track

» Pseudomonas: Start of clinical Phase II/III trials in ventilated 
Intensive   Care Unit patients expected in December 2008

» S. aureus: Phase II study by Intercell's partner Merck & Co. Inc. 
in   cardiothoracic surgery progressing well with efficacy data 
expected by mid   2009 - further Phase II study initiated in 
hemodialysis patients with late-   stage kidney disease, expanding 
the field of application of the vaccine

» Pneumococcus: After full preparation of clinical strategy, start of
clinical   Phase I trials planned for early 2009

Results from 6-month follow-up of Intercell's therapeutic Hepatitis C
vaccine showed statistically significant and long-term antiviral 
effect in Phase II patients

» Intercell is currently examining options for future development 
including   the formulation of the vaccine with IC31® and combination
with other   antiviral therapies

Therapeutic Monoclonal Antibodies

» Strategic partnering process initiated to extract maximum value out
of this   franchise and to keep internal focus on vaccines

Financial Statements

» Intercell's aggregate revenues doubled from EUR 12.6 m in the 9 
months ended   September 30, 2007 to EUR 25.3 m in the same period of
2008

» Intercell's net loss decreased by EUR 8.3 m, or 37.6 percent, to 
EUR 13.8 m   in the first 9 months of 2008 from EUR 22.1 m in the 
same period of 2007

» As of September 30, 2008 Intercell had liquid funds of EUR 209.0 m,
of which   EUR 49.1 m was cash and EUR 159.9 m was available-for-sale
financial assets

» Cash preservation is the principal goal of Intercell's short-term 
cash   management strategy. The impact of the current conditions in 
the capital   markets on the cash portfolio is therefore minimal

KEY FIGURES - FINANCIAL HIGHLIGHTS

EUR in thousands     3 months ended     9 months ended     Year ended
                    Sept 30,  Sept 30  Sept 30  Sept 30,     Dec 31,
                     2008      2007     2008     2007         2007

Revenues            7,641      7,375   25,283   12,559       53,349
Net profit/loss    (5,140)    (6,514) (13,789) (22,085)       5,009
Net operating
 profit/loss       24,956    (12,978)    (430) (27,480)      41,686

Cash and market-
 able securities,
 end of period    208,952    218,580  208,952  218,580      284,571

end of announcement                               euro adhoc

Further inquiry note:

Intercell AG
Lucia Malfent
Head of Communications
Tel. +43 1 20620-1303
lmalfent@intercell.com

Branche: Biotechnology
ISIN: AT0000612601
WKN: A0D8HW
Index: ATX Prime, ATX
Börsen: Wiener Börse AG / official market